We’ve received Notices of Allowance for critical claims across three US Patents—each representing a key pillar of our innovation strategy:
- Technology licensed from VCOM for blood storage (U.S. Patent No. 17/263,526)
- Xheme’s proprietary multifunctional additives (XMA) (U.S. Patent No. 17/390,199)
- Xheme’s proprietary multifunctional additives (XMA) in polymeric elastomers (U.S. Patent No. 17/664,253)
These advances reflect our commitment to pushing boundaries to protect cells and enhance bioprocessing with Xheme’s advanced polymer composite technologies, in advanced materials, sustainability, and biomedical applications. Grateful to our collaborators and team for driving this forward.
